Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 October 2020 | Story Leonie Bolleurs | Photo Supplied
Vicky Simpson believes our current reality is temporary and that we are more than capable to adjust, regardless of our understanding of what ‘normal’ is.

Vicky Simpson is Development Officer in the Office for Institutional Advancement at the university, where one of her main focus areas is to secure funding for UFS projects and raising funds for student bursaries and the No Student Hungry Programme. 

Simpson, an energetic and proactive person who has a passion for interventions that are humanitarian in nature, says she considers herself lucky to be able to align that which she is passionate about with her career, where she can promote the greater good and create opportunities for others.

“I love working with people and I draw energy from interpersonal interactions. I am an extrovert.”

But the strict lockdown regulations implemented by government in March due to the COVID-19 pandemic, which limited personal interaction – dampened Simpson’s enthusiasm for life.

“The side effect was constant snacking – given that the fridge was next to my temporary office. My energy took a dip and I gained weight.”

Keeping positive

“My partner being a frontline medical worker added additional challenges, given that we had to implement strict routines to keep COVID-19 out of our home. We were both rather drained and had to find ways to keep each other positive.”

Practical as she is, Simpson determined that she craved interaction and fresh air.

“I decided to do video calls with friends and family. This made up for the lack of social contact.”

For fresh air, Simpson started a light exercise routine once South Africans were allowed to go for walks, and gradually increased it. “Exercise and healthy nutritional choices lifted my mood. Basically, I used my time wisely and decided to change my routine for the better,” Simpson adds.

She says the key is to set small goals and to take things slowly. “One small victory at a time.” 

Healthy choices

The pandemic challenged Simpson to embrace a more active lifestyle. “The situation forced me to do introspection, self-care, and nurturing,” she says.

Her advice to others is to make the tough choices. “It is easy to get caught up in a routine where you can’t find the time to go for a walk. Evaluate your routine. Start slowly. And do not forget to drink lots of water, take your vitamins, and eat healthier,” she adds.

Simpson explains that she started off by walking only 30 minutes every second day. But once the serotonin bug bit her, she was hooked. Now she goes for a 5 km run at least once a week. “I simply want to feel healthier again,” she says.

She believes our current reality is temporary and she is looking forward to life after lockdown. 

And what is she looking forward to most? Seeing other people smile. “Yes, I randomly smile at strangers. They always smile back. There is not enough love in this world and small things go a long way,” she says.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept